Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium lactis UBBLa-70 + fructooligosaccharide
- Development stage
- Unknown
- Lead developer
- Unique Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium lactis UBBLa-70 + fructooligosaccharide is a synbiotic formulation consisting of a specific probiotic strain, *Bifidobacterium lactis* UBBLa-70, and a prebiotic fiber, fructooligosaccharide (FOS). This combination is designed to synergistically modulate the gut microbiota to improve host metabolic health, particularly in the context of obesity and metabolic syndrome. Clinical research, including trial NCT02505854, has demonstrated that this synbiotic can alter serum metabolite profiles—such as increasing pyruvate and alanine while decreasing branched-chain amino acids (BCAA) and citrate—which are linked to reduced fat mass and systemic inflammation when used alongside a low-energy diet. The probiotic component, UBBLa-70, was originally developed by UAS Labs (now part of Chr. Hansen).
- Other names
- Bifidobacterium lactis UBBLa-70 and fructooligosaccharideB. lactis UBBLa-70 + FOS
Beyond the preview
Go deeper on Bifidobacterium lactis UBBLa-70 + fructooligosaccharide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium lactis UBBLa-70 + fructooligosaccharide.